Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Panobinostat (LBH589) in Combination with the β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both in Vitro and In Vivo

Ioanna Savvidou, MD, Tiffany Khong, BSc, PhD, Sophie Whish, Tara Sepehrizadeh, Sridurga Mithraprabhu, PhD MSc, Michael DeVeer, BSc, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 5540.

https://doi.org/10.1182/blood-2019-126468

Published: 2019

Journal Articles

Resistance to Nutrient Deprivation Via Metabolic Re-Programming As Mechanism of 'Metastasis' Promotion in Multiple Myeloma

Ioanna Savvidou, MD, Sahan Chandrasekara, MD, Maoshan Chenn, PhD, Tiffany Khong, BSc, PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2018) 132 (Supplement 1): 3218.

https://doi.org/10.1182/blood-2018-99-112802

Published: 2018

Journal Articles

The Role of Autophagy in Multiple Myeloma Progression

Ioanna Savvidou, MD, Tiffany T. Khong, BSc,PhD, Andrew Spencer, MD

Blood (2017) 130 (Supplement 1): 5355.

https://doi.org/10.1182/blood.V130.Suppl_1.5355.5355

Published: 2017

Journal Articles

Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients

Sridurga Mithraprabhu, PhD MSc, Ioanna Savvidou, MD, Malarmathy Ramachandran, Anna Kalff, MBBS, Tiffany T. Khong, BSc,PhD, Kate Reed, John Reynolds, PhD, Andrew Spencer, MD

Blood (2017) 130 (Supplement 1): 1823.

https://doi.org/10.1182/blood.V130.Suppl_1.1823.1823

Published: 2017

Journal Articles

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

Antonia Reale, MD Oncologist in training, Tiffany Khong, BSc, PhD, Sridurga Mithraprabhu, PhD, John Reynolds, Malarmathy Ramachandran, Ioanna Savvidou, MD PhD, Krystal Bergin, Jay Hocking, MD PhDstudent, Andrew Spencer

Blood (2016) 128 (22): 4461.

https://doi.org/10.1182/blood.V128.22.4461.4461

Published: 2016

Journal Articles

In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma

Ioanna Savvidou, MD PhDstudent, Tiffany T. Khong, PhD, Stephen K. Horrigan, PhD, Andrew Spencer

Blood (2015) 126 (23): 1816.

https://doi.org/10.1182/blood.V126.23.1816.1816

Published: 2015

Journal Articles

TOP2A Knockdown Resensitizes Carfilzomib-Resistant Hmcls to Carfilzomib

Antonia Reale, Oncologist in training, Tiffany T. Khong, BSc, PhD, Sridurga Mithraprabhu, Post doc, Ioanna Savvidou, MD PhDstudent, Malarmathy Ramachandran, Andrew Spencer

Blood (2015) 126 (23): 4215.

https://doi.org/10.1182/blood.V126.23.4215.4215

Published: 2015

Journal Articles

BC2059: An Orally Bioavailable β-Catenin Inhibitor Potently Induces Apoptosis As A Single Agent and In Combination With Bortezomib In Multiple Myeloma

Ioanna Savvidou, MD, Tiffany T. Khong, BSc, PhD, Stephen K. Horrigan, PhD, Andrew Spencer, MD

Blood (2013) 122 (21): 1920.

https://doi.org/10.1182/blood.V122.21.1920.1920

Published: 2013

Journal Articles

Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma with a Novel Orally Bioavailable Beta-Catenin Inhibitor

Ioanna Savvidou, MD, Tiffany T. Khong, BSc, PhD, Stephen K. Horrigan, PhD, Andrew Spencer, MD

Blood (2012) 120 (21): 1842.

https://doi.org/10.1182/blood.V120.21.1842.1842

Published: 2012

Journal Articles

Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).

Athanasios G. Galanopoulos, MD, PhD, Stephanos Papadhimitriou, MD, Ioannis Tsourveloudis, MD, Evridiki Michalis, MD, Theodoros Marinakis, MD, PhD, Anastasia Tsakiridou, MD, Ioanna Savvidou, MD, Vasilios Xanthopoulos, MD, George Theodoropoulos, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Maria Georgiakaki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4907.

https://doi.org/10.1182/blood.V106.11.4907.4907

Published: 2005

Journal Articles

A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Athanasios G. Galanopoulos, MD, PhD, Anastasia Tsakiridou, MD, Eurydiki Michalis, MD, Theodoros Marinakis, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Vasilios Xanthopoulos, MD, Ioanna Savvidou, MD, George Theodoropoulos, MD, Vasiliki Grigoraki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4740.

https://doi.org/10.1182/blood.V106.11.4740.4740

Published: 2005

Journal Articles

Clinical Outcome of the Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with the Hyper-CVAD Protocol.

Theodoros Marinakis, MD, PhD, Athanasios Zomas, MD, Athanasios G. Galanopoulos, MD, PhD, Eurydiki Michalis, MD, George Gortzolidis, MD, Ioannis Tsourveloudis, MD, Ioanna Savvidou, MD, George Theodoropoulos, MD, Stephanos Papadhimitriou, MD, George Paterakis, MD, Vasiliki Grigoraki, MD, Maria Georgiakaki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4588.

https://doi.org/10.1182/blood.V106.11.4588.4588

Published: 2005

Journal Articles

In Multiple Myeloma, Clonal Cells Are Unevenly Distributed among Peripheral Blood B Cell Subpopulations.

Stefanos I. Papadhimitriou, MD, Ioanna Gligori, MSc, Elpiniki Kritikou-Griva, MD, Georgios Gortzolidis, MD, Aggeliki Davea, MD, Georgios S. Paterakis, MD, Eleni Goumakou, MD, Ioanna Savvidou, MD, Vassiliki Grigoraki, MD, Nikolaos I. Anagnostopoulos, MD, Maria Georgiakaki, MD

Blood (2004) 104 (11): 1426.

https://doi.org/10.1182/blood.V104.11.1426.1426

Published: 2004

NARROW

Panobinostat (LBH589) in Combination with the β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both in Vitro and In Vivo

Resistance to Nutrient Deprivation Via Metabolic Re-Programming As Mechanism of 'Metastasis' Promotion in Multiple Myeloma

The Role of Autophagy in Multiple Myeloma Progression

Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

In Vitro and In Vivo Efficacy of a Novel Orally Bioavailable Beta-Catenin Inhibitor-BC2059- As Monotherapy or in Combination with Proteasome Inhibitors in Multiple Myeloma

TOP2A Knockdown Resensitizes Carfilzomib-Resistant Hmcls to Carfilzomib

BC2059: An Orally Bioavailable β-Catenin Inhibitor Potently Induces Apoptosis As A Single Agent and In Combination With Bortezomib In Multiple Myeloma

Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma with a Novel Orally Bioavailable Beta-Catenin Inhibitor

Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).

A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Clinical Outcome of the Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with the Hyper-CVAD Protocol.

In Multiple Myeloma, Clonal Cells Are Unevenly Distributed among Peripheral Blood B Cell Subpopulations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only